GLPwatch
Papers (12034)
Page 129 of 201, ranked by citation count.
- Brown Adipose Tissue Mimicking Head and Neck Cancer on PET Scan in a Patient on GLP-1 Drug.
- Comparing the Efficacy of Liraglutide and Semaglutide on Weight Loss: Experience from the Middle East Gulf Region and Literature Review.
- Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).
- Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
- Liraglutide Improves Diabetic Cardiomyopathy by Downregulation of Cardiac Inflammatory and Apoptosis Markers.
- GLP-1 receptor agonists for treating obesity without diabetes: A systematic review and meta-analysis of economic evaluations.
- Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study.
- Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.
- Conjugation to a cell-penetrating peptide drives the tumour accumulation of the GLP1R antagonist exendin(9-39).
- The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
- Combination therapy with Exendin-4 and islet transplantation as a synergistic treatment for diabetic nephropathy in rats.
- In-vivo half-life and hypoglycemic bioactivity of a fusion protein of exenatide and elastin-based polypeptide from recombinant Saccharomyces cerevisiae.
- After 10 Years of Clinical Trials with Liraglutide in Diabetes, What do we Know About its Effects on Clinical Cardiovascular Outcomes?
- Suppressed thyroid stimulating hormone levels after initiation of a subcutaneous glucagon-like peptide-1 receptor agonist in a post-thyroidectomy patient managed with levothyroxine case report.
- GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice.
- The Effect of Semaglutide on Gut Microbiota in Chinese Patients with Type 2 Diabetes Poorly Controlled by Metformin.
- Weighing the Risks: Small Bowel Obstruction Associated With Semaglutide Use in the Postoperative Abdomen.
- Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity.
- Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
- New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov.
- The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin.
- Unraveling the safety profile of GLP-1 receptor agonists: Mechanistic insights with a focus on semaglutide.
- Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1.
- Liraglutide restores late cardioprotective effects of remote preconditioning in diabetic rats via activation of hydrogen sulfide and nuclear factor erythroid 2-related factor 2 signaling pathway.
- Unlocking the potential of glucagon-like peptide-1 receptor agonists in revolutionizing type 2 diabetes management: a comprehensive review.
- Next-generation GLP-1 therapy: an introduction to liraglutide.
- Tirzepatide and the Prevention of Heart Failure in Obesity: A Multi-Center Cohort Study Using the TriNetX Database.
- Impact of semaglutide exposure on fetal and neonatal outcomes in pregnant women: a systematic review.
- Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double-Blind Single-Centre Study.
- Understanding the activation mechanism of GLP-1R/GIPR by dual agonist Tirzepatide via molecular dynamics and protein-peptide binding.
- [Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes].
- Alzheimer's disease and type 2 diabetes: what is the connection?
- Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: Protocol for a systematic review and meta-analysis.
- Preparation and evaluation of lactic acid acylated exenatide and its long-acting preparation.
- Oral semaglutide for weight loss and liver fibrosis in overweight and obesity: A randomized controlled trial.
- No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes.
- Treatment of Type 2 Diabetes in Patients with Obesity: A Review.
- Prediction of pediatric dose of tirzepatide from the reference adult dose using physiologically based pharmacokinetic modelling.
- Acquisition of absorption-enhancing abilities of cationic oligopeptides with short chain arginine residues through conjugation to hyaluronic acid.
- Systematic Review and Meta-Analysis of the Efficacy and Safety of Metformin and GLP-1 Analogues in Children and Adolescents with Diabetes Mellitus Type 2.
- Erratum: efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37:2149-2158.
- Comparison of the injection-site experience of semaglutide in a single-dose and a multidose pen-injector.
- Effect of Exenatide on Nonalcoholic Steatohepatitis and Inflammation-Related Indices in Diabetic Patients with Non-Alcoholic Fatty Liver Disease.
- The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD/MASH in Type 2 Diabetes Mellitus: A Narrative Review.
- Recognizing overweight and obesity as chronic diseases and acknowledging root causes.
- GLP-1 receptor agonists: why is once weekly inferior to once daily?
- Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss.
- Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation.
- Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide.
- Efficacy and Safety of Escalating the Dose of Oral Semaglutide from 7 to 14 mg: A Single-Center, Retrospective Observational Study.
- New antihyperglycaemic agents and cardiovascular disease: let's be optimistic.
- Mortality and Serious Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System.
- Semaglutide and obesity: beyond the nutritional and lifestyle intervention?
- Efficacy and Safety in a Real-World Study of the New Oral Formulation of Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.
- Rate and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy with Semaglutide Use for Diabetes and Weight Loss: A Systematic Review and Meta-Analysis.
- A novel antihypertensive effect of exenatide, a GLP-1 agonist.
- GLP-1 and amylin receptor multiagonism with amycretin for obesity management.
- Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.
- Effect of glucagon-like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta-analysis.
- Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies.